Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Bristol Discontinues Tequin, Citing Lack Of Commercial Potential

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

The antibiotic was the subject of recent safety concerns.

You may also be interested in...



Sanofi’s Ketek Is New Target Of Congressional Scrutiny Of FDA

Sen. Grassley requests that senior CDER staff address allegations of inappropriate approval of Sanofi-Aventis’ antibiotic Ketek in May 1 letter.

Sanofi’s Ketek Is New Target Of Congressional Scrutiny Of FDA

Sen. Grassley requests that senior CDER staff address allegations of inappropriate approval of Sanofi-Aventis’ antibiotic Ketek in May 1 letter.

Tequin Merits Black Box Reconsideration For Dysglycemia, Editorial Says

Bristol’s gatifloxacin is “strongly associated with subsequent hospital care for hypoglycemia and hyperglycemia,” NEJM study finds.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug

See All
UsernamePublicRestriction

Register

PS064076

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By